Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00675948
Recruitment Status : Completed
First Posted : May 12, 2008
Results First Posted : September 13, 2012
Last Update Posted : June 24, 2013
Sponsor:
Information provided by (Responsible Party):
GW Pharmaceuticals Ltd.

Brief Summary:
The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex® and GW-2000-02.

Condition or disease Intervention/treatment Phase
Pain Cancer Drug: Sativex Drug: GW-2000-02 Phase 3

Detailed Description:
Subjects who have previously participated in GWCA0101, a two week (two days baseline and two weeks treatment period), multicentre, double blind, randomised, placebo controlled, parallel group study to evaluate the efficacy of Sativex® (containing delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) and GW-2000-02 (containing THC alone) in subjects with cancer-related pain are screened, and if eligible begin dosing with open-label Sativex®. They are allowed to self-titrate their study medication to symptom resolution or maximum tolerated/allowable dose of 130 mg THC and 120 mg CBD and have the opportunity to request a change from Sativex® to GW-2000-02 if they or the investigator consider their response less than optimal. Subjects are reviewed for tolerability and evidence of clinical benefit at 7-10 days after Visit 1 and then every four weeks. Continuation within the study is conditional on satisfactory reports of tolerability, efficacy and dosing regime.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: An Open-label, Extension Study, to Investigate the Long-term Safety and Tolerability of Cannabis Based Medicine Extracts in Patients With Cancer-related Pain.
Study Start Date : April 2002
Actual Primary Completion Date : September 2006
Actual Study Completion Date : September 2006

Arm Intervention/treatment
Experimental: Sativex
Active treatment
Drug: Sativex

Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.

Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.

Other Name: GW-1000-02

Experimental: GW-2000-02
Active treatment
Drug: GW-2000-02
Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.




Primary Outcome Measures :
  1. The Incidence of Adverse Events as a Measure of Subject Safety [ Time Frame: 0 - 657 days ]
    The number of subjects who experienced an adverse event in this study is presented.


Secondary Outcome Measures :
  1. Change From Baseline in the Mean Brief Pain Inventory (Short Form) - Pain Severity Score at the End of Treatment [ Time Frame: 0 - 657 days ]
    The Brief Pain Inventory (Short Form) is a 14-item questionnaire that asks subjects to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items (range 0-10). The minimum value is zero and maximum is 10. A negative value indicates an improvement in score from baseline. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of the mean Brief Pain Inventory (Short Form) score was only carried out when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.

  2. Change From Baseline in the Mean EORTC Quality of Life-C30 Questionnaire - Global Health Status Score at the End of Treatment [ Time Frame: 0 - 657 days ]
    The EORTC Quality of Life-C30 Health Status visual analogue scale was a self-reported score where subjects rated their health state from: 0 = worst health state imaginable to 100 = best health state imaginable. An increase in score from baseline indicates an improvement in condition. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of mean EORTC Quality of Life-C30 Health Status scores was only produced when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and eligible to continue into the extension study from GWCA0101.
  • Complied adequately with the study requirements, as detailed in GWCA0101.
  • In the investigator's opinion able to undertake and comply with all of the study requirements (it is understood that progress of the disease may accelerate and affect this ability).
  • Willing and able to read, consider and understand the subject information and consent form and to give written informed consent in compliance with the Declaration of Helsinki1.
  • Willing to allow their own general practitioner, and consultant if appropriate, to be informed of study participation.
  • Willing for their name to be notified to the Home Office for participation in the trial.

Exclusion Criteria:

  • Have not participated in GWCA0101.
  • Have not complied adequately with the study requirements, as detailed in GWCA0101.
  • Experienced an unacceptable adverse event, whilst participating in GWCA0101.
  • Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness.
  • History of any type of schizophrenia, any other psychotic illness, a serious personality disorder, or other significant psychiatric illness other than depression associated with their chronic pain and/or in response to the underlying condition.
  • Currently taking levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®).
  • Has a serious cardiovascular disorder, including angina, uncontrolled hypertension, or an uncontrolled symptomatic cardiac arrhythmia.
  • Has significant renal or hepatic impairment, which in the opinion of the investigator, are unsuitable for treatment with Investigational Medicinal Product.
  • History of epilepsy.
  • Female subjects of child bearing potential and male subjects whose partner is of child bearing potential, unless willing to ensure that they or their partner use effective contraception during the study and for three months thereafter.
  • If female, are pregnant or lactating, or are planning pregnancy during the course of the study and for three months thereafter.
  • Have oral cavity cancers or whose previous treatments had included radiotherapy to the floor of the mouth.
  • In the opinion of the investigator, are unsuitable to participate in the study for any other reason, not mentioned in the inclusion and exclusion criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00675948


Locations
Layout table for location information
United Kingdom
Shropshire and Mid-Wales Hospice
Shrewsbury, United Kingdom, SY3 8HS
Sponsors and Collaborators
GW Pharmaceuticals Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Jeremy R Johnson, MB ChB Shropshire and Mid-Wales Hospice

Publications of Results:
Layout table for additonal information
Responsible Party: GW Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier: NCT00675948     History of Changes
Other Study ID Numbers: GWEXT0101
First Posted: May 12, 2008    Key Record Dates
Results First Posted: September 13, 2012
Last Update Posted: June 24, 2013
Last Verified: June 2013

Keywords provided by GW Pharmaceuticals Ltd.:
Palliative Care
Pain
Cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Cancer Pain
Pain
Neurologic Manifestations
Signs and Symptoms
Nabiximols
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs